Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

(2020) Calvin J Gordon et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

(2020) Roujian Lu et al.   LANCET

Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission

(2020) Xintian Xu et al.   Science China-Life Sciences

Remdesivir as a possible therapeutic option for the COVID-19

(2020) Jaffar A. Al-Tawfiq et al.   Travel Medicine and Infectious Disease

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

(2020) Canrong Wu et al.   Acta Pharmaceutica Sinica B

A Genomic Perspective on the Origin and Emergence of SARS-CoV-2

(2020) Yong-Zhen Zhang et al.   CELL

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

(2020) Shuai Xia et al.   CELL RESEARCH

The anti‐HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV‐2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID‐19 infections

(2020) Farhana Musarrat et al.   JOURNAL OF MEDICAL VIROLOGY

Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant

(2020) Maria Pachetti et al.   Journal of Translational Medicine

Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity

(2020) Yuanmei Zhu et al.   JOURNAL OF VIROLOGY

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

(2020) Ivan Fan-Ngai Hung et al.   LANCET

Structure of replicating SARS-CoV-2 polymerase

(2020) Hauke S. Hillen et al.   NATURE

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

(2020) David E. Gordon et al.   NATURE

Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

(2020) Zhenming Jin et al.   NATURE

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

(2020) Jason D. Goldman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

(2020) Wenhao Dai et al.   SCIENCE

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

(2020) Yan Gao et al.   SCIENCE

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

(2020) Linlin Zhang et al.   SCIENCE

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

(2020) Xiuyuan Ou et al.   Nature Communications

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19

(2020) Richard T. Eastman et al.   ACS Central Science

Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19

(2020) Jiansheng Huang et al.   Journal of Clinical Medicine

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

(2020) Yuan Huang et al.   ACTA PHARMACOLOGICA SINICA

Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites

(2020) Ashleigh Shannon et al.   ANTIVIRAL RESEARCH

The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity

(2020) Qianqian Li et al.   CELL

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

(2020) Chunlong Ma et al.   CELL RESEARCH

Mutations Strengthened SARS-CoV-2 Infectivity

(2020) Jiahui Chen et al.   JOURNAL OF MOLECULAR BIOLOGY

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates

(2020) Kizzmekia S. Corbett et al.   NEW ENGLAND JOURNAL OF MEDICINE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

(2020) Alina Baum et al.   SCIENCE

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

(2020) Johanna Hansen et al.   SCIENCE

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice

(2020) Athri D. Rathnayake et al.   Science Translational Medicine

Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of IK(M) or IK(DR) and in the Stimulation of IMEP

(2020) Wei-Ting Chang et al.   Frontiers in Pharmacology

The SARS-CoV-2 main protease as drug target

(2020) Sven Ullrich et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19

(2020) Martin Martinot et al.   CLINICAL INFECTIOUS DISEASES

Self-amplifying RNA vaccines for infectious diseases

(2020) Kristie Bloom et al.   GENE THERAPY

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

(2020) Lucy van Dorp et al.   INFECTION GENETICS AND EVOLUTION

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19

(2020) Christoph D. Spinner et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Impact of Early Pandemic Stage Mutations on Molecular Dynamics of SARS-CoV-2 Mpro

(2020) Olivier Sheik Amamuddy et al.   Journal of Chemical Information and Modeling

Genomic and proteomic mutation landscapes of SARS‐CoV‐2

(2020) Christian Luke D. C. Badua et al.   JOURNAL OF MEDICAL VIROLOGY

Exploring the structural distribution of genetic variation in SARS-CoV-2 with the COVID-3D online resource

(2020) Stephanie Portelli et al.   NATURE GENETICS

Biochemical screening for SARS-CoV-2 main protease inhibitors

(2020) Camila Coelho et al.   PLoS One

Paving the Road for RNA Therapeutics

(2020) Niels Dammes et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Commentary: SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Alexandra Lindsey Zune Djomkam et al.   Frontiers in Oncology

mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases

(2019) Giulietta Maruggi et al.   MOLECULAR THERAPY

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

(2019) Egor Tchesnokov et al.   Viruses-Basel

Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors

(2019) Robert N. Kirchdoerfer et al.   Nature Communications

Application of Aptamers in Virus Detection and Antiviral Therapy

(2019) Xinran Zou et al.   Frontiers in Microbiology

mRNA vaccines — a new era in vaccinology

(2018) Norbert Pardi et al.   NATURE REVIEWS DRUG DISCOVERY

Tapping the RNA world for therapeutics

(2018) Judy Lieberman   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

(2018) Merrill D. Benson et al.   NEW ENGLAND JOURNAL OF MEDICINE

RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution

(2018) Sangita Venkataraman et al.   Viruses-Basel

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

(2018) Maria L. Agostini et al.   mBio

Tapping the RNA world for therapeutics

(2018) Judy Lieberman   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The mechanism of resistance to favipiravir in influenza

(2018) Daniel H. Goldhill et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Clinical Application of MicroRNAs in Infectious Disease

(2017) Ruth E. Drury et al.   Frontiers in Immunology

Mechanisms of viral mutation

(2016) Rafael Sanjuán et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfected, treatment-naïve patients

(2016) Ying Cao et al.   Clinics and Research in Hepatology and Gastroenterology

mRNA-based therapeutics — developing a new class of drugs

(2014) Ugur Sahin et al.   NATURE REVIEWS DRUG DISCOVERY

Nucleolin Interacts with the Dengue Virus Capsid Protein and Plays a Role in Formation of Infectious Virus Particles

(2013) C. A. Balinsky et al.   JOURNAL OF VIROLOGY

Treatment of HCV Infection by Targeting MicroRNA

(2013) Harry L.A. Janssen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Progress of RNA Aptamer-Based Therapeutics

(2012) Jiehua Zhou et al.   Frontiers in Genetics

The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension

(2011) Aartjan J.W. te Velthuis et al.   NUCLEIC ACIDS RESEARCH

siRNA vs. shRNA: Similarities and differences

(2009) Donald D. Rao et al.   ADVANCED DRUG DELIVERY REVIEWS

Novel Dual Inhibitory Function Aptamer–siRNA Delivery System for HIV-1 Therapy

(2008) Jiehua Zhou et al.   MOLECULAR THERAPY